Tarsus Pharmaceuticals Inc
$ 67.24
-0.71%
17 Apr - close price
- Market Cap 2,861,566,000 USD
- Current Price $ 67.24
- High / Low $ 69.68 / 66.66
- Stock P/E N/A
- Book Value 8.07
- EPS -1.59
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.23 %
- 52 Week High 85.25
- 52 Week Low 38.51
About
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Analyst Target Price
$95.11
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-04 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-09 | 2023-08-10 | 2023-05-09 |
| Reported EPS | -0.2 | -0.3 | -0.48 | -0.64 | -0.6 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 | -1.17 | -0.88 |
| Estimated EPS | -0.0836 | -0.35 | -0.38 | -0.63 | -0.8157 | -0.94 | -0.92 | -1.2 | -1.36 | -1.37 | -1.08 | -0.94 |
| Surprise | -0.1164 | 0.05 | -0.1 | -0.01 | 0.2157 | 0.33 | 0.04 | 0.19 | 0.05 | 0.09 | -0.09 | 0.06 |
| Surprise Percentage | -139.2344% | 14.2857% | -26.3158% | -1.5873% | 26.4435% | 35.1064% | 4.3478% | 15.8333% | 3.6765% | 6.5693% | -8.3333% | 6.383% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.29 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARS
2026-04-18 06:09:41
Wall Street Zen downgraded Tarsus Pharmaceuticals (NASDAQ:TARS) to a "Hold" rating, though the MarketBeat consensus remains a "Moderate Buy" with an average price target of $91.83. Insider selling has been significant, with the CEO and a director offloading shares, while institutional investors hold approximately 90% of the stock. Tarsus Pharmaceuticals' lead candidate, OC-01, is in Phase 3 development for dry eye disease.
2026-04-17 23:10:16
Tarsus Pharmaceuticals (TARS) has experienced a 16.4% decline in the past four weeks, making it appear oversold based on its Relative Strength Index (RSI) of 19.34. This, combined with strong agreement among Wall Street analysts in raising earnings estimates and a Zacks Rank #1 (Strong Buy), suggests a potential for a near-term rebound. Investors are advised to consider TARS as a buying opportunity given these technical and fundamental indicators.
2026-04-13 11:09:41
Tarsus Pharmaceuticals (NASDAQ:TARS) has received a consensus "Moderate Buy" rating from nine brokerages, with an average one-year target price of $91.83. Despite this positive outlook from analysts, company insiders have been net sellers, disposing of over $5.43 million in shares over the past 90 days. The company recently reported a slight EPS miss but exceeded revenue estimates.
2026-04-12 21:09:53
This article analyzes Tarsus Pharmaceuticals Inc. (TARS), highlighting strong market sentiment and a significant risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strength, support, and resistance levels for TARS.
2026-04-06 17:40:04
Tarsus Pharmaceuticals has initiated a Phase 2 trial for TP-05, an oral prophylactic for Lyme disease, marking the company's expansion beyond eye care into infectious disease prevention. This development could transform its investment narrative by diversifying its product pipeline beyond its existing commercial asset, XDEMVY, while also leveraging its lotilaner platform. The company's financial projections indicate significant revenue and earnings growth by 2028, with some analysts forecasting even higher figures.
2026-04-06 09:11:15
Capricorn Fund Managers Ltd significantly reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 90.8% in the fourth quarter, selling 218,038 shares. This divestment leaves them with 21,982 shares valued at approximately $1.8 million. Several company insiders have also been net sellers, with the CEO and General Counsel selling shares totaling over $1 million, while analysts maintain a "Moderate Buy" consensus rating with an average target price of $91.83.
